KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Charles River Laboratories International (CRL) Long-Term Debt Repayments (2016 - 2025)

Charles River Laboratories International has reported Long-Term Debt Repayments over the past 17 years, most recently at $207.8 million for Q4 2025.

For Q4 2025, Long-Term Debt Repayments rose 17.56% year-over-year to $207.8 million; the TTM value through Dec 2025 reached $1.3 billion, down 9.67%, while the annual FY2025 figure was $1.3 billion, 9.67% down from the prior year.
Long-Term Debt Repayments for Q4 2025 was $207.8 million at Charles River Laboratories International, down from $253.8 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $2.5 billion in Q2 2021 and troughed at $149.4 million in Q1 2025.
A 5-year average of $643.5 million and a median of $368.9 million in 2022 define the central range for Long-Term Debt Repayments.
Biggest five-year swings in Long-Term Debt Repayments: skyrocketed 2004.1% in 2021 and later plummeted 83.41% in 2023.
Year by year, Long-Term Debt Repayments stood at $1.1 billion in 2021, then tumbled by 61.21% to $408.2 million in 2022, then fell by 21.43% to $320.8 million in 2023, then crashed by 44.89% to $176.8 million in 2024, then increased by 17.56% to $207.8 million in 2025.
Business Quant data shows Long-Term Debt Repayments for CRL at $207.8 million in Q4 2025, $253.8 million in Q3 2025, and $738.3 million in Q2 2025.